IN8bio, Inc.
INAB
$0.1449
$0.01219.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -28.17% | -14.50% | -19.24% | -1.34% | 7.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.53% | -21.49% | -15.73% | 12.62% | 10.06% |
| Operating Income | 34.53% | 21.49% | 15.73% | -12.62% | -10.06% |
| Income Before Tax | 35.18% | 18.93% | 1.16% | -11.85% | -13.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.18% | 18.93% | 1.16% | -11.85% | -13.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.18% | 18.93% | 1.16% | -11.85% | -13.78% |
| EBIT | 34.53% | 21.49% | 15.73% | -12.62% | -10.06% |
| EBITDA | 37.04% | 23.23% | 16.90% | -14.08% | -10.48% |
| EPS Basic | 66.38% | 63.58% | 34.14% | 29.45% | 35.00% |
| Normalized Basic EPS | 66.34% | 63.60% | 44.01% | 29.46% | 37.73% |
| EPS Diluted | 65.00% | 63.58% | 34.14% | 29.45% | 34.28% |
| Normalized Diluted EPS | 66.34% | 63.60% | 44.01% | 29.46% | 37.73% |
| Average Basic Shares Outstanding | 92.86% | 122.66% | 50.01% | 58.49% | 75.02% |
| Average Diluted Shares Outstanding | 92.86% | 122.66% | 50.01% | 58.49% | 75.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |